To Market Qsymia, Vivus Takes On Additional Debt
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the weight-loss drug haven’t been brisk, but Vivus can fortify its balance sheet with up to $110 million in debt. Analysts say it could raise more soon, provided it gains a regulatory victory.
You may also be interested in...
Vivus’ Qsiva Down But Not Out At EMA; Lundbeck Will Write Off Acrescent
Vivus’ decision to fight CHMP rejection of Qsiva is a worthy cause, but Lundbeck confirms that Acrescent’s not unexpected elimination is the end of the line for the Alzheimer’s drug combination.
REMS For Qsymia Limits Distribution, But Vivus To Explore Expanding Access
Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.
FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients
A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies